LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 06/18/24

Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research org...

(TheNewswire) Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives Kelowna, British Columbia – June 18, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a glo...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study...

(TheNewswire) Second study arm dosing is now complete. Kelowna, British Columbia – June 5, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to the announcement, this is the first-ever DehydraTECH(TM)-processed tirzepatide from...

(TheNewswire) First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format Kelowna, British Columbia – May 23, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company”...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has received two new patent awards, bringing the company’s patent portfolio to 43 granted patents worldwide. According to the announcement, the company has been granted a patent in its patent family #...

(TheNewswire) Kelowna, British Columbia – TheNewswire - May 21, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces two important new patent...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs ...

--News Direct-- Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? Kelowna, British Columbia – May 17, 2024 – TheNewswire – Lexaria Biosc...